reports
Outlook Therapeutics Expands European Footprint with Exclusive Commerc...
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasda...
Dime Awards Grant to LIEOC for Community Services
Dime Awards Grant to LIEOC for Community Services HAUPPAUGE, N.Y., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced that Dime has awarded a grant to Long Island Economic Opportunity Collaborative ("LIEOC") in support of academic and vocational training opportunities designed to foster personal growth, career advancement, and social mobility services in Nassau and Suffolk counties. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial ...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for ...
- Jonathan Moreland
VRNS VARONIS SYSTEMS INC.
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TWI TITAN INTERNATIONAL INC.
SLP SIMULATIONS PLUS
SCSC SCANSOURCE INC.
PSEC PROSPECT CAPITAL CORPORATION
PAYX PAYCHEX INC.
NG. NOVAGOLD RESOURCES INC.
MOH MOLINA HEALTHCARE INC.
MMS MAXIMUS INC.
LMAT LEMAITRE VASCULAR INC.
KVHI KVH INDUSTRIES INC.
GKOS GLAUKOS CORP
CINF CINCINNATI FINANCIAL CORPORATION
BMI BADGER METER INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
ARCC ARES CAPITAL CORPORATION
ASA ASA
PRU PRUDENTIAL PLC
TSI TCW STRATEGIC INCOME FUND INC.
PLBC PLUMAS BANCORP
GRF EAGLE CAPITAL GROWTH FUND INC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
PW POWER REIT
ABT ABBOTT LABORATORIES
KKR KKR & CO. INC.
AXR AMREP
SONO SONOS
TENB TENABLE HOLDINGS
AVTR AVANTOR
CMTV INC.
AON COMMUNITY BANCORP INC. VT
BSTZ AON PLC CLASS A
AFRM BLACKROCK SCIENCE AND TECHNOLOGY TRUST II
INTA AFFIRM HOLDINGS
TMC INTAPP INC
CHRW TMC THE METALS CO INC
TBBK C.H. ROBINSON WORLDWIDE
FRST INC.
QDEL THE BANCORP
CHUC INC.
PMN PRIMIS FINANCIAL CORP
HYMC QUIDEL CORP
CING CHARLIES HLDGS INC
SPGI PROMIS NEUROSCIENCES INC.
HYCROFT MINING HOLDING CORPORATION
CINGULATE INC
MCGRAW HILL FINANCIAL INC
- Jonathan Moreland
KVHI KVH INDUSTRIES INC.
ASA ASA
PRU PRUDENTIAL PLC
TSI TCW STRATEGIC INCOME FUND INC.
GRF EAGLE CAPITAL GROWTH FUND INC
ZIVO ZIVO BIOSCIENCE
AXR INC.
AVTR AMREP
AON AVANTOR
BSTZ INC.
TBBK AON PLC CLASS A
NPWR BLACKROCK SCIENCE AND TECHNOLOGY TRUST II
FIG THE BANCORP
SPGI INC.
NET POWER INC
FIGMA INC.
MCGRAW HILL FINANCIAL INC
Outlook Therapeutics Submits Type A Meeting Request to FDA Following C...
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following receipt of a Complete Response Letter (CRL) dated December 30, 2025, regarding the Company’s Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of ...
- Jonathan Moreland
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Off...
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, partn...
Dime Announces Intention to Redeem Subordinated Debt and Reauthorizati...
Dime Announces Intention to Redeem Subordinated Debt and Reauthorization of Share Repurchase Plan HAUPPAUGE, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company”) announced its intention to redeem at par on March 30, 2026, all of its outstanding $40,000,000 principal amount of Fixed/Floating Subordinated Debentures (the "Debentures") due 2030. The proposed redemption is part of the Company’s ongoing capital management strategy and reflects its strong capital position and liquidity profile. The redemption of the Debentures is expected to be funded with cas...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series A Preferred Stock HAUPPAUGE, N.Y., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM, DCOMP and DCOMG) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.34375 per share on the Company’s 5.50% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series A, payable on February 13, 2026 to holders of record as of February 6, 2026. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a...
Dime Community Bancshares, Inc. Reports Strong Fourth Quarter Results ...
Dime Community Bancshares, Inc. Reports Strong Fourth Quarter Results with Earnings Per Share Increasing By 15% On a Linked Quarter Basis Record Quarterly Revenue of $124 Million Organic Growth Strategy and The Hiring of Teams is Paying Dividends With Linked Quarter Growth in Core Deposits of Approximately $800 Million and Business Loans of Over $175 Million HAUPPAUGE, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the "Company" or "Dime"), the parent company of Dime Community Bank (the "Bank"), today reported net income available to common stock...
Dime Community Bancshares to Release Earnings on January 21, 2026
Dime Community Bancshares to Release Earnings on January 21, 2026 HAUPPAUGE, N.Y., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the "Company") today announced that the Company expects to release its earnings for the quarter ended December 31, 2025 before the open of the U.S. equity markets on Wednesday, January 21, 2026. The Company will conduct a conference call at 8:30 a.m. (ET) on Wednesday, January 21, 2026, during which President and Chief Executive Officer (“CEO”), Stuart Lubow, will discuss the Company’s fourth quarter financial performance. The...
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker ...
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company’s transforma...
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corp...
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s tw...
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug ...
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the ONS-5010/LYTENAVA™ (bevacizumab-vikg) biologics license...
Outlook Therapeutics Announces New Employment Inducement Grants
Outlook Therapeutics Announces New Employment Inducement Grants ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees. The above-described awards were gran...
Dime Awards Grant to Junior Achievement
Dime Awards Grant to Junior Achievement HAUPPAUGE, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced that Dime has awarded a grant to Junior Achievement of Long Island in support of their mission to provide financial literacy, career readiness, and entrepreneurship education for low-to-moderate income communities. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered tr...
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This com...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Deve...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., De...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common Stock HAUPPAUGE, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on January 23, 2026 to common stockholders of record as of January 16, 2026. The Company continues its trend of uninterrupted dividends. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trus...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.